Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study

por Wolf, Christian, Sidhu, Jagdev, Otoul, Christian, Morris, Dexter L., Cnops, Jennifer, Taubel, Jorg, Bennett, Barbara
Publicado 2013